Skip to search formSkip to main contentSkip to account menu

Ibrutinib

Known as: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)- 
An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration… 
National Institutes of Health

Related topics

Related topics

6 relations
Ibrutinib 140 MG Oral CapsuleIbrutinib 140 MG Oral Capsule [Imbruvica]NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

Imbruvica

Broader (1)

PCI 32765

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Waldenström macroglobulinemia (WM), an incurable B-cell malignancy, is sensitive to Bruton tyrosine kinase (BTK) inhibition with… 
2018
2018
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple… 
2018
2018
A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation
Background: Outcomes of patients (pts) with Richter transformation (RT) remain dismal with a median survival of less than 1… 
Review
2018
Review
2018
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic…
BACKGROUND: Chronic lymphocytic leukemia (CLL) is one of the most common lymphoid malignancies, accounting for ~11% of all… 
Highly Cited
2017
Highly Cited
2017
Ibrutinib may impair serological responses to influenza vaccination
We write to share our experience with serological failure of standard influenza vaccine in patients treated with the novel Bruton… 
Highly Cited
2017
Highly Cited
2017
Synthesis, Pharmacokinetics, Pharmacodynamics, Dosing, Stability, Safety and Efficacy of Orphan Nano Drugs to Treat High Cholesterol and Related Conditions and to PreventCardiovascular Disease Under…
Orphan Nano drugs such as Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif… 
Highly Cited
2015
Highly Cited
2015
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses are infrequent, and… 
2015
2015
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies
In this phase I dose-escalation study we evaluated the safety, tolerability, pharmacokinetics, and antitumor activity of… 
2013
2013
Irreversible kinase inhibitors gain traction
The approval of Boehringer Ingelheim's anticancer drug afatinib highlights the growing enthusiasm for once-shunned irreversible… 
Review
2013
Review
2013
Treatment strategies for aggressive lymphomas: what works?
  • W. Wilson
  • Hematology. American Society of Hematology…
  • 2013
  • Corpus ID: 206861522
Over the past 30 years, many treatment platforms have been developed for diffuse large B-cell lymphoma, but none proved better… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)